Tag Archive for: PharmaMar

Lurbinectedin  is a synthetic derivative of trabectedin (ET-743) originally isolated from the sea squirt Ecteinascidia turbinata.PharmaMar SA
Lung cancer

FDA approves atezolizumab–lurbinectedin for ES-SCLC

The U.S. FDA has approved atezolizumab and atezolizumab with hyaluronidase in combination with lurbinectedin as the first and only first-line maintenance therapy for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after induction therapy with atezolizumab, carboplatin and etoposide.

Read more
Prof. Dr. José Maria Fernández Sousa-Faro, Chairman of PharmaMar's Board of Director.© PharmaMar SA
EMA

EMA-Gate: PharmaMar wins suit against EMA

The European Commission has fully upheld the complaint by PharmaMar SA due to conflicts of interest of leading EMA experts in the (non-)authorisation of Aplidin.

Read more